Pharma producer Gilead Sciences is looking to produce a new hepatitis C treatment in Egypt jointly with a local manufacturer, Trade and Industry Minister Tarek Kabil says. According to Al Masry Al Youm, Kabil says Gilead wants to use Egypt as a gateway market to African nations. The medication still awaits FDA approval, he added; Gilead Senior Director Graeme Robertson says the proposed treatment is administered for two months and has a 98% success rate. Robertson added that Egypt is the only country in Africa that has the required infrastructure to produce the treatment.

Tags: